SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: michael s. who wrote (624)4/25/1997 12:08:00 AM
From: George T. Santamaria   of 6136
 
Let me suggest that everytime AGPH announces a new R&D effort, somebody sees a potential cash burner siphoning away profits. Remember, AGPH has another Phase II/III effort underway with Thymitaq and it is gonig to burn cash the way that Viracept did. Furthermore, Thymitaq does not have as big a market as Viracept.

The Nastech thing represents the grand challenge of all pharmaceutical R&D efforts. The market is huge and maybe your grandchildren will make out big time from this one.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News